Advertisement
Advertisement
VIVS
VivoSim Labs, Inc. Common Stock
1.39
USDSponsored
-0.02
-1.42%
May 08, 16:00 UTC -4
Closed
After-Market
1.43
+0.04
+2.52%
VIVS Earnings Reports
Positive Surprise Ratio
VIVS beat 19 of 21 last estimates.
90%
Next Report
Date of Next Report
Jun 03, 2026
Estimate for Q4 25 (Revenue/ EPS)
$46.92K
/-$0.19
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q4 24 (Revenue/ EPS)
+61.79%
/-94.54%
VivoSim Labs, Inc. Common Stock earnings per share and revenue
On --, VIVS reported earnings of -- USD per share (EPS) for -- --, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to Q4 25, 3 analysts forecast an EPS of -0.19 USD, with revenue projected to reach 46.92 thousand USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Werewolf Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+3.68%
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
FAQ
What were VivoSim Labs, Inc. Common Stock's earnings and revenue for the latest quarter Q-- --?
For Q-- --, VivoSim Labs, Inc. Common Stock reported EPS of --, Inline estimates by --, and revenue of --, -- -- expectations.
How did the market react to VivoSim Labs, Inc. Common Stock's Q-- -- earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is VivoSim Labs, Inc. Common Stock expected to report next?
The next earning report is scheduled for Jun 03, 2026.
What are the forecasts for VivoSim Labs, Inc. Common Stock's next earnings report?
Based on 3
analysts, VivoSim Labs, Inc. Common Stock is expected to report EPS of -$0.19 and revenue of $46.92K for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement